TTrialPathMatch Me to Trials
← Back to trials
RecruitingUnruptured Brain Arteriovenous MalformationRuptured Brain Arteriovenous MalformationArteriovenous Malformations

Treatment of Brain AVMs (TOBAS) Study

Eligible age

5+ yrs

Accepts

All genders

Locations

3 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The objectives of this study and registry are to offer the best management possible for patients with brain arteriovenous malformations (AVMs) (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty. Management may include interventional therapy (with endovascular procedures, neurosurgery, or radiotherapy, alone or in combination) or conservative management. The trial has been designed to test a) whether medical management or interventional therapy will reduce the risk of death or debilitating stroke (due to hemorrhage or infarction) by an absolute magnitude of about 15% (over 10 years) for unruptured AVMs (from 30% to 15%); and, b) to test if endovascular treatment can improve the safety and efficacy of surgery or radiation therapy by at least 10% (80% to 90%). As for the nested trial on the role of embolization in the treatment of Brain AVMs by other means: the pre-surgical or pre-radiosurgery embolization of cerebral AVMs can decrease the number of treatment failures from 20% to 10%. In addition,embolization of cerebral AVMs can be accomplished with an acceptable risk, defined as permanent disabling neurological complications of 8%.

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

You may qualify if…

  • Any patient with a brain AVM

You may not qualify if…

  • Hemorrhagic presentation with mass effect requiring surgical management. In these cases, if a residual AVM is found after the initial surgery, the patient could then be a candidate for TOBAS.

Where it's recruiting

Florida

Jacksonville

New Mexico

Albuquerque

Source: ClinicalTrials.gov · NCT02098252 · last updated 2024-08-15